Down 25%, Should Bristol Be a Dip Buy Right Now Today?
When a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
A straightforward comparison of the Djia and the S&P 500, focusing on diversification, volatility profiles, and historical performance to guide decision making.
22,615 articlesWhen a blue-chip pharma stock falls 25%, many investors wonder if it's time to buy. This guide breaks down how to ass...
AI data centers are expanding fast, backed by major cloud players. This article dives into why hyperscalers plan spen...
As 2025 unfolds, MediWound faces a pivotal year for debt, cash, and milestones. This analysis breaks down what mediwo...
The White House confirmed the firing of a National Transportation Safety Board member amid misconduct allegations, wh...
In a Friday decision, the Tenth Circuit refused to hear Custodia Bank's final appeal, ending a five-year battle for d...
Western Midstream Partners raised its quarterly distribution to $0.93 per unit, pushing the annualized payout to $3.7...
MRCC unveiled a $0.75 special distribution tied to reserve funds as it merges with HRZN. Despite the payout, investor...
Kyndryl’s latest quarterly results triggered a notable stock move as earnings fell short of expectations. This articl...
EDIV has outperformed on yield-focused EM plays, but the next year hinges on the dollar’s next move will drive curren...
A new wave of proposals aims to tighten how decentralized finance operates in the U.S. Senate. These clarity amendmen...
The popular image of Annaly Capital focuses on its hefty dividend. But the real investment story sits in the balance ...
Gossamer Bio's 2026 earnings outlook centers on cash runway, pipeline progress, and strategic partnerships. This arti...